HealthWise at 5 From 10.21 - KCBD NewsChannel 11 Lubbock

10/21/05

HealthWise at 5 From 10.21

  • PSA Study

The PSA test is a simple test that measures a specific antigen in the blood that is linked to prostate cancer, but new evidence from Harvard points to how valuable that test really is. Researchers there found that men who had a yearly PSA blood test were nearly three times less likely to die from prostate cancer than those who did not have the annual screenings. Prostate cancer is easily cured, when it is diagnosed early.

  • Exercise Study

Researchers in Germany warn against waiting until the golden years to start thinking about osteoporosis. The International Osteoporosis Foundation has issued a report that highlights exercise as one of the main ways to reduce your risk of getting the disease. Scientists say bone matter needs regular stimulation from physical activity or it will deteriorate. An estimated 10-million Americans suffer from osteoporosis. Study led by researchers at the International Osteoporosis Foundation and presented in Berlin as part of World Osteoporosis Day

  • Diabetes Drug

Researchers who sounded the alarm about heart risks linked to the arthritis drug Vioxx are raising a red flag now about an experimental drug for type two diabetes. Cardiologists at the Cleveland Clinic say their research shows the drug Pargluva doubles the risk of heart attack, stroke and death. In September, an FDA panel voted to approve Pargluva for type two diabetes. Now, after reviewing five clinical trials involving nearly four thousand people, the Cleveland Clinic is suggesting the drug's risks may outweigh its potential benefits, and the FDA is asking for more research. The review is published in a special online release of the Journal of the American Medical Association.

Powered by WorldNow

5600 Avenue A
Lubbock, TX. 79404

FCC Public File
publicfile@kcbd.com
806-744-1414
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and KCBD. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.